FDA Approves Unknown Drug — WATSON LABS

On October 6, 2010, Watson Labs received final approval from the FDA for its Abbreviated New Drug Application (ANDA) No. 091129, a move that immediately prompted a cut in list prices for the indicated medication. Following this favorable regulatory action, the stock rallied as investors anticipated net revenue increases derived from market share gains against the originator product.